COMPARISON SOFTWARE TO ASSESS NGS ACCURACY & BOOST TRANSLATIONAL RESEARCH

评估 NGS 准确性的比较软件

• 批准号: 10081512
• 负责人: Xing Xu
• 金额: $ 25.17万
• 依托单位: SOLVE, INC.
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-01 至 2021-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10081512
• 关键词: Academic Medical Centers; Address; Adoption; Benchmarking; Bioinformatics; Biological; Biological Assay; Cancer Diagnostics; Clinical Research; Clinical Trials; Complex; Computer software; Copy Number Polymorphism; Data; Data Set; Detection; Diagnostic; Generations; Genetic; Genomics; Goals; Health; Individual; Informatics; Intelligence; Manuals; Methods; Monitor; Mutation; Oncology; Online Systems; Output; Patient Rights; Patients; Pharmacologic Substance; Phase; Publications; Reporting; Reproducibility; Research; Right to Treatments; Role; Scientist; Small Business Innovation Research Grant; Source; Structure; Technology; Testing; Time; Tissues; Translational Research; Tumor-Derived; Variant; Vendor; Visualization; actionable mutation; application programming interface; base; biomarker development; clinical care; cloud based; commercial application; companion diagnostics; data format; design; experience; flexibility; genomic biomarker; gigabyte; graphical user interface; improved; insight; liquid biopsy; multimodal data; multiple omics; mutation assay; next generation sequencing; open source; precision medicine; precision oncology; research and development; screening; software systems; statistics; targeted treatment; technological innovation; tool; tumor DNA; virtual

Project Summary SolveBio is a cloud-based data platform for biopharma clinical and translational research. The goal of this project is to implement a graphical user interface-based comparison software suite to flexibly compare next generation sequencing (NGS) results for patients across replicates, assays, commercial vendors, biospecimens, and timepoints, with an initial application in assessing liquid biopsy accuracy. Liquid biopsy is an emerging non-invasive method for screening and monitoring actionable mutations but technological and biological hurdles remain. Comparing and evaluating NGS data generated by different assays is difficult to impossible for most individual scientists. Solving this challenge has the potential to catalyze progress in the adoption of precision oncology and facilitate the broader application of next-generation sequencing technologies to provide more efficient clinical care to patients.

项目摘要 SolveBio是一个基于云的生物制药临床和转化研究数据平台。的 本项目的目标是实现一个基于图形用户界面的比较软件套件 为了灵活地比较重复样本之间患者的下一代测序（NGS）结果， 分析、商业供应商、生物标本和时间点，最初应用于 评估液体活检准确性。液体活检是一种新兴的非侵入性方法， 筛选和监测可行的突变，但技术和生物障碍仍然存在。 比较和评估由不同测定法生成的NGS数据是困难的， 大多数科学家解决这一挑战有可能促进在以下方面取得进展： 采用精确肿瘤学，促进下一代肿瘤学的更广泛应用 测序技术，为患者提供更有效的临床护理。